Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers. 1 The overall survival rate of patients with advanced HCC remains unsatisfactory as a high incidence of recurrence and metastasis after liver resection has been noted. 2, 3 Therefore, it is very important to elucidate the underlying mechanisms and find novel biological markers for prognosis of HCC.
Recently, Wang et al 4 reported that RNA-binding motif 4 (RBM4) suppresses proliferation and migration in various cancers by specifically controlling cancer-related splicing. The study indicated that RBM4, as a tumor suppressor, had therapeutic potential and clinical value. However, there is no report on the study of RBM4 expression in HCC. Roles of RBM4 in development and prognosis of HCC remain unknown. This study aimed to study the relationship between RBM4 expression and the prognosis of HCC after liver resection.
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chen et al January 2010 to December 2015. Preoperative evaluation protocol included blood biochemistry, chest radiography, liver and renal function tests, ultrasonography and computed tomography scan. Liver resection was performed in the patients with good cardiopulmonary and renal function and Pugh-Child's grades A and B. All patients were followed up for tumor recurrence by clinical examination, alpha feto protein and ultrasonography.
Participants
Our research was in compliance with the Helsinki Declaration. The ethics approval and consent in study were approved by the Ethics Committee of Shaoxing Second Hospital, Zhuzhou Clinical Institute, Central South University School of Medicine and the Fourth Affiliated Hospital, Zhejiang University School of Medicine. Prior written informed consent was obtained from all patients for this study.
immunohistochemistry Formalin-fixed paraffin sections were stained for RBM4 using anti-human RBM4 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the streptavidin-peroxidase system (Zhongshan Goldenbridge Biotechnology, Beijing, People's Republic of China). Negative control slides were probed with goat serum followed by the secondary antibody (Zhongshan Goldenbridge Biotechnology) under the same conditions. The expression levels of RBM4 were scored using a 4-point scale according to the percentage of positive hepatocytes: 0, the percentage of positive hepatocytes was no more than 10%; 1, the percentage of positive hepatocytes was 10%-25%; 2, the percentage of positive hepatocytes was 25%-50%; 3, the percentage of positive hepatocytes was more than 50%. The protein expression of RBM4 was thus considered as low expression if the score was 0 or 1; a score of 2 or 3 was considered as high expression. RBM4 expression in HCC specimens was also divided into low-expression group (score 0 or 1) and high-expression group (score 2 or 3).
statistical analysis
All data were analyzed using the statistical software Statistical Package for the Social Sciences (SPSS) 19 for Windows (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as mean ± standard deviation and compared using the independent-samples t-test. Survival analysis was estimated by the Kaplan-Meier survival method and compared using the log-rank test. The log-rank was compared between the survival of patients with low and high RBM4 expression.
Multivariate analysis by the Cox proportional hazard regression model was used to identify independent prognostic factors. P,0.05 was considered to be statistically significant.
Results
clinicopathologic features of patients
Ninety-five HCC patients without any preoperative treatment received liver resection from January 2010 to December 2015. Of the 95 patients (Table 1) , there were 75 patients with hepatitis B infection. Sixty-one patients had liver cirrhosis, association between rBM4 expression and the clinicopathologic characteristics of hcc
Immunohistochemistry showed that RBM4 expression was significantly low (25.3%) in HCC tissues (Table 1) . According to the immunohistochemistry results, all HCC patients were divided into two groups: the high-expression group in which RBM4 expression scored 2 or 3 (n=24) (Figure 1 ) and the low-expression group in which RBM4 expression scored 1 or 0 (n=71). We found that RBM4 expression negatively correlates with hepatitis B infection (P=0.039). The RBM4 expression in patients with liver cirrhosis was significantly lower than in those without liver cirrhosis (P=0.033).
The RBM4 expression also has significant relationship with tumor number (P=0.047). The patients with capsular formation had higher RBM4 expression than those without capsular formation (P=0.041). The expression of RBM4 in patients with vascular invasion was lower than those without vascular invasion (P=0.003). The patients in UICC stage I had higher RBM4 expression than the patients in stages II-III (P=0.046). The RBM4 expression level also had significant relationship with BCLC stage (P=0.001) ( Table 1) .
association between rBM4 expression and the overall survival rate of hcc
Overall survival rate was analyzed according to the expression of RBM4 in 95 cases of HCC. RBM4 high-expression group had better overall survival rate than the low-expression group (P,0.001) (Figure 2A association between rBM4 expression and the disease-free survival of hcc
Disease-free survival was also analyzed according to the expression of RBM4 in 95 cases of HCC (Table 3) . RBM4 high-expression group had better disease-free survival rates than the low-expression group (P=0.007) ( Figure 2B 
Discussion
The splicing factor RBM4 suppresses proliferation and migration in various cancers by specifically controlling cancer-related splicing. [5] [6] [7] [8] [9] Wang et al 4 reported that RBM4 regulates Bcl-x splicing to induce apoptosis and RBM4 expression is decreased dramatically in human cancer such as lung, breast and ovarian cancer. Recently, Yong et al 10 found that RBM4 expression is also decreased dramatically in gastric cancer and a reduced RBM4 level is correlated with poor survival rate. However, it is still unknown about the RBM4 expression in HCC. In this study, our result showed that the RBM4 expression was low in HCC tissues. RBM4 high-expression group had better overall survival rate and disease-free survival rate than the low-expression group (P,0.001, P=0.007, respectively). Furthermore, RBM4 expression, together with tumor numbers, capsular formation, vascular invasion and BCLC stage, was as independent prognostic factor for overall and disease-free survival of HCC. These implicated RBM4 as a novel prognostic marker for HCC after liver resection. Interestingly, we found that RBM4 expression negatively correlates with hepatitis B infection and liver cirrhosis. As most HCC cases in People's Republic China were caused by the HBV infection, [11] [12] [13] [14] RBM4 may play an important role in the development of HCC by regulating HBV-related cirrhosis. This part of work remains to be done in our future research.
Subsequently, we found that the RBM4 expression also had significant relationship with tumor number (P=0.047), capsular formation (P=0.041) and vascular invasion (P=0.003). Tumor number together with capsular formation and vascular invasion is related to the invasion and metastasis of HCC.
15-17 Accordingly, we speculate that RBM4 may participant in the invasion and metastasis of HCC. There may remain new factors such as epithelial-mesenchymal transition. Future studies are needed to find out the exact mechanism. 
Conclusion
In conclusion, our study showed for the first time that high expression of RBM4 correlated with better overall survival rate and disease-free survival rate in HCC patients after liver resection. Our data suggested RBM4 as a novel biomarker for HCC. 
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